Navigation Links
Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors
Date:6/11/2008

DANBURY, Conn., June 11 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Barry Ginsberg, M.D., Ph.D., has been elected as a new member of its Board of Directors, effective June 10, 2008. Dr. Ginsberg is currently Chief Executive Officer of Diabetes Technology Consultants where he advises Fortune 500 companies in the field of diabetes.

"We are pleased to welcome Barry to our Board of Directors at such an important time for Biodel," stated Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Barry's diabetes expertise and experience as a seasoned advisor to commercial stage companies will provide invaluable insights and contributions to Biodel as we prepare to file VIAject(TM)'s New Drug Application by the end of 2008."

Dr. Ginsberg joins the Company's Board of Directors with over 25 years of experience in diabetes. Prior to Diabetes Technology Consultants, Dr. Ginsberg served as Vice President of Worldwide Medical Affairs in the Diabetes HealthCare Division at Becton Dickinson during his 17 year tenure. Dr. Ginsberg currently serves as Chairman of the Scientific Advisory Boards at Agamatrix and Therafuse, and is a Scientific Advisory Board Member at Covidien, Metacure, Glucolight and Becton Dickinson Diabetes HealthCare. While a Professor of Medicine at the University of Iowa (1977-90), he was a Principal Investigator of the prestigious Diabetes Control and Complications Trial.

Biodel also announced that Albert Cha, M.D., Ph.D. will depart from the Company's Board of Directors. Dr. Cha, a Managing Partner of Vivo Ventures, joined the Company's Board of Directors in July 2006.

"Albert has been a valued source of counsel and he served our Company and its shareholders well during our transition from an early stage private company to a public company with a late stage Phase III product candidate. We thank him for his service and wish him well," stated Dr. Steiner.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
3. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
4. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
5. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
6. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
7. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
8. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
9. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
10. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
11. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics Inc ... $2M in funding from an impressive group of investors, including Rev1 Ventures, Maumee ... With this investment, 3Bar is broadening availability of its groundbreaking offering that uses ...
(Date:8/16/2017)...  This year,s edition of the Inc. 5000 features a now-familiar name: ... has made the list for the third year in a row. Now ... companies based on a set of quantitative metrics. In addition, BioPoint was ... in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... 2017 After spending the past two years building a ... collection, GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, ... adherence, and data collection vis a vis their members, under their ... launch of this offer. ... ...
(Date:8/15/2017)... Diego, CA (PRWEB) , ... August 15, 2017 ... ... company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch ... the number of steps needed to gain kinetic binding data for a wide ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
Breaking Biology News(10 mins):